Trial
NCT00417248
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Nasser Hanna, M.D.
Collaborators
Bayer; Amgen; Walther Cancer Institute
Condition
Non-Small Cell Lung Cancer
Intervention
Cisplatin
Why stopped
Negative sorafenib results from ESCAPE trial and safety concerns of regimen
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-25